Screener
Kyverna Therapeutics, Inc. KYTX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 5,280 | 3,700 |
| Total current assets | 241,726 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,343 | 1,546 |
| Operating lease right-of-use assets | 8,192 | 3,568 |
| Finance lease right-of-use assets | 198 | 305 |
| Other non-current assets | 5,014 | 4,903 |
| Total assets | $257,024 | $293,826 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s PP&E (net)?
- Kyverna Therapeutics, Inc. (KYTX) reported PP&E (net) of $1.34M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s PP&E (net) changed year-over-year?
- Kyverna Therapeutics, Inc.'s PP&E (net) decreased by 44.9% year-over-year, from $2.44M to $1.34M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s PP&E (net)?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s PP&E (net) has grown at a -18.5% compound annual growth rate (CAGR), from $2.33M to $1.55M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Kyverna Therapeutics, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude